Abstrato

Patient perspectives on switching from intravenous to subcutaneous infliximab and vedolizumab in inflammatory bowel disease: Results from a cross-sectional survey.

Oldenburg L, Wijnands AM, Oldenburg B

Objective: Recently, Subcutaneous (SC) formulations of Infliximab (IFX) and Vedolizumab (VDZ) were approved for clinical use. The present study aims to explore whether patients with Inflammatory Bowel Disease (IBD), receiving Intravenous (IV) IFX or VDZ therapy, prefer IV or SC routes of administration. Methods: We conducted a cross-sectional web-based survey on the willingness to switch from IV to SC administration among IBD patients, treated with IV IFX or VDZ in a large tertiary hospital in the Netherlands. All adult IBD patients (including Crohn’s disease, ulcerative colitis, or IBD-unclassified) visiting the outpatient department for IV administration of IFX or VDZ between June and October 2021 were asked to participate. Predictors for willingness to switch to SC injections were identified by logistic regression analysis. Result: In total, 148 out of 219 patients who agreed to receive the questionnaire, gave informed consent and completed the questionnaire (response rate 68%). Seventy-nine patients (53%) were willing to switch to SC formulations. The most frequently cited reasons for willingness to switch were dependency on hospital-based care and travel time-related issues. Lower treatment satisfaction rates (Likert scale 0-10) and receiving IV therapy <1 year were associated with willingness to switch in, respectively, univariable and both univariable and multivariable analysis. Conclusion: Fifty-three percent of patients with IBD receiving IV therapy is willing to switch to SC injections. Predictors for willingness to switch included lower treatment satisfaction rates (only univariable analysis) and <1 year of IV therapy.